$14.66
4.34% day before yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
JE00BYSS4X48
Symbol
NVCR

Novocure Ltd. Stock price

$14.66
+2.58 21.36% 1M
-2.32 13.66% 6M
-15.14 50.81% YTD
+0.12 0.83% 1Y
-63.22 81.18% 3Y
-103.04 87.54% 5Y
-4.03 21.56% 10Y
-3.62 19.80% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.61 4.34%

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.6 | 2.5
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
29.0%
Return on Equity
-46.8%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$630.2m | $645.6m
EBITDA
$-156.9m | $-58.1m
EBIT
$-169.2m | $-176.8m
Net Income
$-171.0m | -
Free Cash Flow
$-80.4m
Growth (TTM | estimate)
Revenue
14.6% | 6.7%
EBITDA
8.7% | 63.1%
EBIT
7.6% | -4.9%
Net Income
-1.3% | -
Free Cash Flow
23.0%
Margin (TTM | estimate)
Gross
76.6%
EBITDA
-24.9% | -9.0%
EBIT
-26.9%
Net
-27.1% | -
Free Cash Flow
-12.8%
More
EPS
$-1.5
FCF per Share
-
Short interest
8.3%
Employees
1k
Rev per Employee
$410.0k
Show more

Is Novocure Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Novocure Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Novocure Ltd. forecast:

10x Buy
71%
4x Hold
29%

Analyst Opinions

14 Analysts have issued a Novocure Ltd. forecast:

Buy
71%
Hold
29%

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
630 630
15% 15%
100%
- Direct Costs 148 148
11% 11%
23%
483 483
16% 16%
77%
- Selling and Administrative Expenses 439 439
14% 14%
70%
- Research and Development Expense 213 213
1% 1%
34%
-157 -157
9% 9%
-25%
- Depreciation and Amortization 12 12
10% 10%
2%
EBIT (Operating Income) EBIT -169 -169
8% 8%
-27%
Net Profit -171 -171
1% 1%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Novocure Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novocure Ltd. Stock News

Neutral
Business Wire
4 days ago
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three- and nine-month periods that ended September 30, 2025. To access the con...
Neutral
Business Wire
5 days ago
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented today at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 – October 1 in San Francisco and simultaneously p...
Neutral
Business Wire
20 days ago
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. “With the Ministry of Heal...
More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office Jersey
CEO Ms. Cordova
Employees 1,488
Founded 2000
Website www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today